Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

At the five-year celebration event, scientists and health study volunteers from across the DPUK partnership came together to launch one of the world’s most in-depth study's into preclinical Alzheimer’s disease - one of the most important outcomes from DPUK's work to transform dementia research infrastructure in the UK.

The event saw scientists from each of the major research networks in Dementias Platform UK (DPUK) – Imaging, Stem Cells and Informatics – come together with many of the lead researchers of large clinical studies into dementia. The Deep and Frequent Phenotyping study which is about to launch, is an example of one such study, which aims to pinpoint the signs of dementia much earlier in the disease development.

Dementia affects over 50 million people worldwide and is the biggest public health crisis facing us in the 21st century. We have stepped up the fights against it with this multi-million pound investment. Whilst the money is crucial, what is also important with a programme of this kind is that what it can achieve is greater than the sum of its parts.
- Professor John Gallacher, Director of Dementias Platform UK.

 

Read more here.